Trials / Completed
CompletedNCT03107013
A Study to Investigate the Mass Balance of BTD-001
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Balance Therapeutics · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single-centre, open-label, non-randomised, single oral dose study in healthy male subjects to assess the mass balance recovery of carbon-14 (14C)-BTD-001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-BTD-001 | Carbon-14 labeled BTD-001 |
Timeline
- Start date
- 2017-04-03
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2017-04-11
- Last updated
- 2017-10-24
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03107013. Inclusion in this directory is not an endorsement.